Comprehensive Stock Comparison
Compare Inhibrx Biosciences, Inc. (INBX) vs Merus N.V. (MRUS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | MRUS | -12.4% revenue growth vs INBX's -88.9% |
| Quality / Margins | MRUS | -6.5% net margin vs INBX's -110.8% |
| Stability / Safety | INBX | Beta 0.74 vs MRUS's 0.90 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | INBX | +459.5% vs MRUS's +91.1% |
| Efficiency (ROA) | MRUS | -43.4% ROA vs INBX's -87.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapeutics for life-threatening conditions like cancer. It generates no revenue currently — funding operations through equity offerings and partnerships while advancing multiple candidates through clinical trials. Its competitive advantage lies in proprietary single-domain antibody (sdAb) technology platforms that enable creation of multi-specific biologics with potentially superior therapeutic profiles.
Merus N.V. is a clinical-stage biotechnology company developing bispecific antibody therapies for cancer treatment. It generates revenue primarily through research collaborations and licensing deals — with no commercial products yet — while advancing its pipeline through clinical trials. The company's competitive advantage lies in its proprietary antibody discovery platform that enables the creation of novel bispecific antibodies targeting multiple cancer pathways simultaneously.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
MRUS leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
MRUS is the larger business by revenue, generating $51M annually — 36.6x INBX's $1M. MRUS is the more profitable business, keeping -6.5% of every revenue dollar as net income compared to INBX's -110.8%.
| Metric | INBXInhibrx Bioscienc… | MRUSMerus N.V. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $51M |
| EBITDAEarnings before interest/tax | -$151M | -$329M |
| Net IncomeAfter-tax profit | -$155M | -$335M |
| Free Cash FlowCash after capex | -$143M | -$318M |
| Gross MarginGross profit ÷ Revenue | -86.3% | -2.2% |
| Operating MarginEBIT ÷ Revenue | -110.0% | -6.5% |
| Net MarginNet income ÷ Revenue | -110.8% | -6.5% |
| FCF MarginFCF ÷ Revenue | -102.5% | -6.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +13.7% |
Valuation Metrics
| Metric | INBXInhibrx Bioscienc… | MRUSMerus N.V. |
|---|---|---|
| Market CapShares × price | $1.1B | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $930M | $6.5B |
| Trailing P/EPrice ÷ TTM EPS | 0.64x | -26.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5373.68x | 195.71x |
| Price / BookPrice ÷ Book value/share | 8.03x | 8.92x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
MRUS delivers a -50.6% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-4 for INBX. MRUS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to INBX's 0.06x.
| Metric | INBXInhibrx Bioscienc… | MRUSMerus N.V. |
|---|---|---|
| ROE (TTM)Return on equity | -4.2% | -50.6% |
| ROA (TTM)Return on assets | -87.4% | -43.4% |
| ROICReturn on invested capital | — | -74.6% |
| ROCEReturn on capital employed | -169.3% | -48.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.06x | 0.02x |
| Net DebtTotal debt minus cash | -$145M | -$283M |
| Cash & Equiv.Liquid assets | $153M | $293M |
| Total DebtShort + long-term debt | $8M | $10M |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | — |
Total Returns (with DRIP)
A $10,000 investment in MRUS five years ago would be worth $37,768 today (with dividends reinvested), compared to $25,954 for INBX. Over the past 12 months, INBX leads with a +459.5% total return vs MRUS's +91.1%. The 3-year compound annual growth rate (CAGR) favors MRUS at 67.7% vs INBX's 46.1% — a key indicator of consistent wealth creation.
| Metric | INBXInhibrx Bioscienc… | MRUSMerus N.V. |
|---|---|---|
| YTD ReturnYear-to-date | -1.2% | 0.0% |
| 1-Year ReturnPast 12 months | +459.5% | +91.1% |
| 3-Year ReturnCumulative with dividends | +211.6% | +371.9% |
| 5-Year ReturnCumulative with dividends | +159.5% | +277.7% |
| 10-Year ReturnCumulative with dividends | +263.5% | +796.4% |
| CAGR (3Y)Annualised 3-year return | +46.1% | +67.7% |
Risk & Volatility
INBX is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than MRUS's 0.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MRUS currently trades 92.6% from its 52-week high vs INBX's 78.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INBXInhibrx Bioscienc… | MRUSMerus N.V. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 0.90x |
| 52-Week HighHighest price in past year | $94.56 | $97.14 |
| 52-Week LowLowest price in past year | $10.81 | $33.19 |
| % of 52W HighCurrent price vs 52-week peak | +78.4% | +92.6% |
| RSI (14)Momentum oscillator 0–100 | 47.2 | 14.9 |
| Avg Volume (50D)Average daily shares traded | 165K | 520K |
Analyst Outlook
Wall Street rates INBX as "Buy" and MRUS as "Hold".
| Metric | INBXInhibrx Bioscienc… | MRUSMerus N.V. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | — | $97.00 |
| # AnalystsCovering analysts | 5 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | 100 | 398.59 | +298.6% |
| Merus N.V. (MRUS) | 100 | 748.13 | +648.1% |
Merus N.V. (MRUS) returned +278% over 5 years vs Inhibrx Biosciences… (INBX)'s +160%. A $10,000 investment in MRUS 5 years ago would be worth $37,768 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | $7M | $200000.00 | -97.0% |
| Merus N.V. (MRUS) | $2M | $35M | +1730.9% |
Merus N.V.'s revenue grew from $2M (2015) to $35M (2024) — a 38.1% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -124.0% | 8437.9% | +6903.1% |
| Merus N.V. (MRUS) | -12.2% | -6.0% | +51.2% |
Merus N.V.'s net margin went from -12% (2015) to -6% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -0.23 | 116.58 | +50787.0% |
| Merus N.V. (MRUS) | -1.65 | -3.35 | -103.0% |
Merus N.V.'s EPS grew from $-1.65 (2015) to $-3.35 (2024).
Chart 5Free Cash Flow — 5 Years
Inhibrx Biosciences, Inc. generated $-197M FCF in 2024 (-143% vs 2021). Merus N.V. generated $-188M FCF in 2024 (-210% vs 2021).
INBX vs MRUS: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is INBX or MRUS a better buy right now?
Inhibrx Biosciences, Inc. (INBX) offers the better valuation at 0.6x trailing P/E, making it the more compelling value choice. Analysts rate Inhibrx Biosciences, Inc. (INBX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INBX or MRUS?
Over the past 5 years, Merus N.V. (MRUS) delivered a total return of +277.7%, compared to +159.5% for Inhibrx Biosciences, Inc. (INBX). A $10,000 investment in MRUS five years ago would be worth approximately $38K today (assuming dividends reinvested). Over 10 years, the gap is even starker: MRUS returned +796.4% versus INBX's +263.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INBX or MRUS?
By beta (market sensitivity over 5 years), Inhibrx Biosciences, Inc. (INBX) is the lower-risk stock at 0.74β versus Merus N.V.'s 0.90β — meaning MRUS is approximately 23% more volatile than INBX relative to the S&P 500. On balance sheet safety, Merus N.V. (MRUS) carries a lower debt/equity ratio of 2% versus 6% for Inhibrx Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — INBX or MRUS?
Inhibrx Biosciences, Inc. (INBX) is the more profitable company, earning 8438% net margin versus -595.9% for Merus N.V. — meaning it keeps 8438% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRUS leads at -753.0% versus -1657.2% for INBX. At the gross margin level — before operating expenses — MRUS leads at 37.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — INBX or MRUS?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is INBX or MRUS better for a retirement portfolio?
For long-horizon retirement investors, Merus N.V. (MRUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.90), +796.4% 10Y return). Both have compounded well over 10 years (MRUS: +796.4%, INBX: +263.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between INBX and MRUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INBX is a small-cap deep-value stock; MRUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.